Staying Ahead of Progression in RMS

Guest: Timothy William West, MD <br> <p>Here to discuss staying ahead of progression in patients with relapsing multiple sclerosis (RMS) is Dr. Timothy William West. Dr. West walks us through pathophysiological changes in progressing RMS patients, a patient case demonstrating why patients may experience increasing disability, and key data on MAYZENT<strong>^®</strong>(siponimod), the first and only oral disease-modifying therapy studied and proven to delay disability progression in a more progressed RMS patient population, including active SPMS.</p> <p>MAYZENT was evaluated in <em>EXPAND—</em>the largest Phase III study of secondary progressive MS (SPMS) patients to date (N=1651), which included a broad range of patients with moderate-to-advanced disability. Dr. West discusses clinical data from <em>EXPAND</em> including data of up to 5 years from a preplanned interim analysis of the <em>EXPAND</em> open-label extension study.</p>